A treatment by Axial Therapeutics now entering a phase 2 trial indirectly affects brain cells by working on metabolites in the gut. What to know: Biotech company Axial Therapeutics recently raised $37.25 million to fund a phase 2 trial of AB-2004, their molecular therapy intended to treat irritability in children with autism. Axial is exploring